Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Phase 2 Active not recruiting

28 enrolled

Breast

Breast Neoplasms

NCT07367178 2026-01-28

SATROPIN

Phase 2 Not yet recruiting

30 enrolled

Breast

Breast Neoplasms

NCT07368543 2026-01-28

STORM

Phase 2 Not yet recruiting

216 enrolled

Breast

Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Phase 2 Active not recruiting

110 enrolled 26 charts

Breast

Breast Neoplasms

NCT06263543 2025-12-26

SERIES

Phase 2 Recruiting

75 enrolled

Breast

Breast Neoplasms

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Phase 2 Recruiting

15 enrolled

Breast

Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT05675579 2025-11-04

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

27 enrolled

Breast

Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT03971409 2025-05-02

InCITe

Phase 2 Recruiting

150 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2 Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT06236269 2024-07-19

ACROSS-TROP2

Phase 2 Recruiting

50 enrolled

Breast

Breast Neoplasms

NCT06462079 2024-06-17

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Phase 2 Not yet recruiting

43 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

Clinical Trials

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

SATROPIN

STORM

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

SERIES

PRIMED

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Scalp Cooling in MBC

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

ALTER

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

InCITe

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

ACROSS-TROP2

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases